As more cases of COVID-19 are confirmed, we recognize the increased challenges and concerns faced by participants in the …
BioMarin
BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301)
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated …
BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study
Company Plans to Provide Topline Phase 3 Data by Year End Company Presents Data Confirming that the Phase 3 and Phase 2 …
BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced …